¤@¡³¤T¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¤ßŦ¬ì

(A) 1. ¨Ì¾Ú2014¦~·sª©ªºJNC 8ªvÀø°ª¦åÀ£¡A±j½Õ¹êÃÒÂå¾Ç¡A¤U¦C¦ó¶µªº»¡ªk¤£¬O±M®a¤p²Õªº«Øij¡H
A.¤j©ó60·³ªº°ª¦åÀ£¯f¤H¥H§C©ó160/90 mmHg ¬°ªvÀø¥Ø¼Ð¡C
B.¤¶©ó30-59·³ªº°ª¦åÀ£¯f¤H¥H¤ßµÎ¦åÀ£§C©ó90 mmHg ¬°ªvÀø¥Ø¼Ð¡C
C.60·³¥H¤U¿}§¿¯f¤ÎºC©ÊµÇ¯fÅܯf¤Hªº¦åÀ£ªvÀø¥H140/90 mmHg¬°ªvÀø¥Ø¼Ð¡C
D.¿}§¿¯f¤H­°À£°_©lªvÀø¥HAngiotensin-converting enzyme inhibitor, Angiotensin receptor blocker, Calcium channel blocker¤ÎThiazides-type diuretics¬°­­¡C
E.­°À£¾¯¥[¥ÎAngiotensin-converting enzyme inhibitor, Angiotensin receptor blocker¥i§ïµ½ºC©ÊµÇ¯f¤H¤§µÇ¥\¯à¡C
 
(E) 2. ®Ú¾Ú"2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults"¡A½Ð°Ý¤U¦C¦ó¶µ¤£¬O«Øijªº«ü¤Þ¡H
A.¤wª¾µ°ª¬µw¤Æ¯fÅܬÛÃöªº¤ß¦åºÞ¯f¤HÀ³µ¹¤©°ª±j«×¤§StatinªvÀø¡C
B.LDL-C >190 mg/dlªº¤HÀ³µ¹¤©°ª±j«×¤§StatinªvÀø¡C
C.¦~ÄÖ40-75ªº¿}§¿¯f¤H¡A¨äLDL-C¤j©ó70 mg/dl´NÀ³µ¹¤©¤¤µ¥«×¤§StatinªvÀø¡C
D.¦~ÄÖ40-75¯f¤H¡A¨ä¾ãÅé10¦~­·ÀI°ª©ó7.5%¤ÎLDL-C 70-189 mg/dl´NÀ³µ¹¤©¤¤µ¥«×¤§StatinªvÀø¡C
E.LDL-C¤§ªvÀø¥Ø¼Ð¡G¤ß¦åºÞ¯f¤H¤Î¿}§¿¯f¤HÀ³§C©ó70mg/dl¡F¦³¤ß¦åºÞ¯f¦MÀI¦]¤lªÌÀ³§C©ó100mg/dl¡F¨ä¥LªÌÀ³§C©ó160 mg/dl¡C
 
(B) 3. 82·³¦Ñ°ü¤H¨ì°|¥D¶D¤­¤Ñ¨Ó¦³¤éÁÍÄY­«ªº©I§l§xÃø¡C¯f¥vÅã¥Ü30¦~«e´N¦³Âå®v§iª¾¤ßŦÂø­µ¡A¦]µL¯gª¬¡A¥¼´¿¦³¥ô¦óªvÀø¡Cªñ¤­¦~¨Ó¹B°Ê­@¨ü³vº¥¤£¨Î¡A¥B°¸¦³¬ðµo©Ê±ª°Ê¤Î¤ßµ±µh¡A¯S§O¦b¨B¦æ¼Ó±è¶¡§ó¥[´c¤Æ¡C¦í°|·í¤é²M±á3ÂI¬ðµM­««×©I§l§xÃø¡A¦]¦Ó«æ¶E¦í°|¡C²z¾ÇÀˬd¡G¦åÀ£110/62 mmHg¡F¤ß¸õ90/¤À¡FÀVÀR¯ß«ã±i¡C¤ßŦ¤j¤p¥¿±`¡A¦ý¦b¥k¤W¯Ý°©½t¤Î¤ß¦y³¡¦³Gr III/VI systolic murmur, S2´î»´¡G¨ä¥L©Ò¨£©|µL²§±`¡C¨ä¯Ý³¡X¥ú¡B¤ßŦ¶W­µªi¤Î¤ß¹q¹Ï¦p¹Ï¡CWBC,5.2 k/micro L¡FAST,21U/L¡FCK,111U/L¡FCK-MB,14.6U/L¡FTroponin I,0.06 ng/ml¡C½Ð°Ý¤U¦C¦ó¶µ³B¸m³Ì«ê·í?
A.Percutaneous coronary intervention
B.Aortic valve replacement
C.Nitroglycerin IV infusion at the rate of 15mcg/min
D.Titrate PO carvedilol starting from 3.125 mg and reassess in 3 months
E.Treating with IV digoxin 0.125mg in conjunction with IV bolus Furosemide 20mg and then 20 mg BID
 
(D) 4. ¯f¤H67·³¨k©Ê¡A¦Û7¤ë°_¦³»´«×«y¹Â¤Î¶¡Â_©Êµo¿N°ª¹F38«×¡A§{¶¡¶E©Ò¶EÂ_¬°¤W©I§l¹D·P¬V¡Cº¸«á¡Aµo¿N¤´Â°_¥ñÅÜ°Ê¡A°¸¦³´HŸ(chillness)¡A¨Ã¦³¥þ¨­­Â«å¤Î¤G¤½¤çÅé­«´î»´¡Aª½¨ì11¤ë¤~¨ì°|¨D¶E¡C¯f¤H¶È¦³°ª¦åÀ£¯f¥v¡AªAÃĤ¤¡C²z¾ÇÀˬd¡G¦åÀ£¡A132/70 mmHg¡F¤ß¸õ¡A78/¤À¡A¥¿±`«ß°Ê¡F¤ßŦ¦³Gr II/IV Systolic murmur over left lower sternum border¡F¨ä¥L©|µL²§±`©Ò¨£¡CBlood cultures °eÀˤ¤¡C ½Ð°Ý¥»¯f¤Hªº¶EÂ_¥H¦ó¶µÀˬd³Ì«ê·í?
A.Cardiac MRI
B.Chest CT
C.Gallium Scan
D.Transesophageal echocardiography
E.Exploratory chest operation
 
(C) 5. ¤ßŦ°IºÜ¯f¤H±`¦³¨x¡BµÇ¥\¯àµ¥¦h­«¾¹©x²§±`¤Î±`­n¨Ö¥Î¦hºØÃĪ«¡A¥i¼vÅTÃĪ«ªº§l¦¬¤Î±Æªn¡A¾É­P¥ÎÃĥ椬§@¥Î¸T§Òªºµo¥Í¡A½Ð°Ý¤U¦C¦óºØÃĪ«±o¨Ï¥Î?
A.Thiazolidinediones
B.Dronedarone
C.Amlodipine
D.Cyclooxygenase 2 inhibitors
E.Metformin
 
(C) 6. 72·³¦Ñ¥ý¥Í¡A©]¶¡ºÎı¤¤¬ð¦]¯Ý¯k¦ñ¦³´HŸ¡B§N¦½¦ÓÅå¿ô¡A¯kµh³vº¥¥[¼@¡A¨Ã©µ¦ù«á­I³¡¡A¤D«æ­u«æ¶E³¡¨D¶E¡C·í®É¦åÀ£¥ª¤â176/98 mmHg¡F¥k¤â164/97 mmHg¡F¯ß¸õ78/¤À¡A³W«h¸õ°Ê¡C¯f¤H°l¾Ðªñ­Ó¤ë¨Ó¡A®É¦³¶¡·²©Êªº¯Ýµh¡A¦³®É¬Æ¦Üµh¹L­Ó§â¤p®É¡C ¯f¤H³ß¦n©â·Ï¡A¦ý©|µL¨ä¥L¯e¯f¡C²z¾Ç¥u¨£¨­°ª 176 cm¤ÎÅé­«64.6 kg¡A¦åÀ£¤Î¤ß¸õ¦p«e©Ò­z¡A¤W¤UªÏ°Ê¯ß¸õ°Ê¥¿±`¡A¨ä¥L³¡¦ì¨ÃµL²§±`¥i¨£¡C¨ä¯Ý³¡X¥ú¡B¤ß¹q¹Ï¤Î¹q¸£Â_¼h¦p¹Ï¡C¹êÅç«ÇÀˬd¦p¤U¡C¸g¨Ï¥ÎIV morphine¤ÎÂíÀR¾¯«á¡A¯fªp¤j¦³§ïµ½¡C½Ð°Ý¦¹¨è¯f¤H³Ì¦X©yªºªvÀøµ¦²¤¬O?
A.Endovascular stenting
B.Urgent aortic repair
C.Labetalol IV titration
D.Catheter-based fenestration
E.Dopamine IV infusion
 
(E) 7. ¦³Ãö¤ß«Ç§Ö¸õ(Ventricular tachycardia, VT)ªº»¡ªk¡A¤U¦C¦óªÌªº»¡ªk¬O¿ù»~ªº¡H
A.Monomorphic VT ¦h¨£©ó«D¾¹©xÅܲ§©Ê¤ßŦ¯f¡C
B.Polymorphic VT¦bEP ¹êÅç«Ç¤£©ö¹q¿E¾É»¤µo(Electric stimulation)¡C
C.¦å¦æ¤O¾Ç²§±`¤Î¥hŸ¹q¿E¦³®ÄªºVT¦h¬O«ùÄò©ÊVT(Sustained VT)¡C
D.¦b¤ß«e°Ï¹q·¥(Precordial leads) ¥X²{¦P­P©Ê(Concordant)QRS«¬ºA¡C
E.Monomorphic VT ¨Ï¥ÎÀRª`ªºProcainamide,Lidocaine ©ÎAmiodarone ´N¦³®Ä¡A¤£¥²¹qÀ»¡C
 
(C) 8. ¨Ì¾Ú¬ü°êÂå®v¾Ç°|(American College of Physicians)°ò©óÂåÀø¦¨¥»¡BÁ{§É¹ê®Ä¤Î¯f¤H¦w¥þ¡A¦³¤U¦C½Ñ¶µ·ÓÅ@³B¸m¡G(1)¤¤¦~¤k©Ê¡A¦³¥¿±`¤ë¸g¶g´Á¡A¤]¨S¦³¥ô¦ó¤ßŦ¯gª¬¡A¥¼¦³¤T°ª¯f¥v¡A¬°¦­´Á¶EÂ_¡A¹F¨ì§¹¥þªvÀø®ÄªG¡AÀ³«Øij¹q¸£Â_¼h«aª¬°Ê¯ß³y¼vÀˬd¡A¥HÁA¸Ñ«a¯ß¯U¯¶¤Î«aª¬°Ê¯ß¶t¤Æ¤À¼Æ (2)¤G¦yä²æ««¯f¤H¶i¦æ©Þ¤ú¤â³N®É¡A°£¦³¤ß¤º½¤ª¢¯f¥v¥~¡A¥i¤£¥²ªA¥Î§Ü¥Í¯À¹w¨¾¤ß¤º½¤ª¢¤§µo¥Í (3)ºC©Ê«a¤ß¯f¤H¡A¦bÃĪ«ªA¥Î¤¤¡A¥¼¦³¥ô¦ó¤ßŦ¯gª¬®É¡A¤£¥²¥H«aª¬°Ê¯ß³y¼v°lÂܵ°ª¬µw¤Æ¤§¶i®i (4)«æ©Ê¤U¾À¤ß¦Ù±ð¶ë¦ñµo§¹¥þ©Ð«Ç¶Ç¾Éªýº¢¡AÀ³­Ôµ¥¼Æ¤Ñ¡A¤~¥i¨M©w¸m©ñ¥Ã¤[©Ê¤ß«ß½Õ¾ã¾¹ (5)¤ßŦ°IºÜ¯f¤H¨Ö¦³©I§l§xÃø®É¡A¤´ÂÂÀ³¦³BNPÀË´ú¡A¥H¬°ªvÀø¤§°Ñ¦Ò¡C½Ð°Ý¤U¦C¦ó²Õªº³B¸m¤~¦³°ª»ù­Èªº·ÓÅ@¡H
A.(1)+(3)+(5)
B.(1)+(4)+(5)
C.(2)+(3)+(4)
D.(2)+(4)+(5)
E.(3)+(4)+(5)
 
(E) 9. ªL¥ý¥Í¦~27·³¡A©ó2013¦~10¤ëªì±q¤¤°ê¤u§@¦^¥x«á¡A¶}©l¦³«y¹Â¡B¶¡·²©Ê´HŸ¡BÂm¨{¤Î»´«×©I§l§xÃø¡A¸g¹L¤G¶g¡A¯fª¬¤é¼@¡A¥þ¨­­Â«å¡A¨Ã¦³ºÝ§¤©I§l§xÃø¡A¸¡µÈ¡Bäú¤ß¤ÎÅé­«¼@¼W¡A¤D¦í°|¶EÀø¡C²zÀËÅã¥Ü¡G¨­°ª¡A179¤½¤À¡FÅé­«¡A84.6¤½¤ç¡FÅé·Å36.9«×¡G¤ß¸õ 110/¤À¡F©I§l 24/¤À¤Î¦åÀ£ 159/119 mmHg¡FÀVÀR¯ß«ã±i¡FÂù°¼ªÍ¦³²V¿B©I§lÁn¡F¤ßŦ¡AS3¤Îleft lift¡A¦ýµL¤ßŦÂø­µ¥i»D¡F¸¡³¡¦³shifting dullness¡A¦ýµL¨x¸~¡FÂù¸}¯B¸~¡C¨ä¤ß¹q¹Ï¡B¤ßŦ¶W­µªi¤Î¯Ý³¡X¥ú¦p¹Ï¡C ½Ð°Ý³o¯f¤H³Ì¥i¯àªº¶EÂ_¬O¡G
A.Acute myocardial infarction
B.Hypertensive cardiovascular disease
C.Hypertrophic cardiomyopathy
D.Acute aortic disease
E.Acute heart failure
 
(C) 10. §ù¥ý¥Í73·³¡A¦]H1N1¬y¦æ©Ê·P«_¨ÖµoªÍª¢¤Î©I§l°IºÜ¦Ó©ó1¤ë24¤é¦í°|¡C¦³©â·Ï¯f¥v¡A¦ýµL°ª¦åÀ£¡B¿}§¿¯f©Î¦å¯×²§±`¯f¥v¡C¦í°|¤¤©I§l¤´Â¤£¾A¡A1¤ë26¤é²M±á¦å®ñ­°§C¡A®ÉT/P/R 36.8/123/26¡FCVP=8mmHg¡ABP 140/73mmHg¡Abilateral crackles¡A±Ò¥Î PEEP»²§U©I§l¡Cºò«æ¤ß¹q¹Ï¤Î¯Ý³¡X-¥úÀˬd¦p¹Ï¡C½Ð°Ý¥»¯f¤H¤§¶EÂ_¬O¡G
A.Acute respiratory failure
B.Acute lungs edema
C.STEMI, proximal left anterior descending artery occlusion
D.STEMI, proximal right coronary artery occlusion
E.NSTEMI, left circumflex artery occlusion
 
(D) 11. 72·³¨k©Ê¦Ñ¤H¡A¦í°|¥D¶D¬ðµo©Ê©I§l§xÃø¡C¯f¤H¦b2007¦~¦³°ª¦åÀ£ªA¥ÎBisoprolol(5mg)1/2 #,qd¤Î Amlodipine(5mg) 1#,qd¡C2009¦~7¤ë6¤éªñ¥G©ü³Ö¨DÂå¡A¤ß¹q¹Ï¦p(A)¡C2003¦~4¤ë1¤é¦³¥ª²´¥¢©ú¤Î¥ª¤â³n®zµL¤O¡A®É¦åÀ£164/79 mmHg¤Î¤ß¸õ93/min¡A¤£³W«h«ß¸õ¡A¤ß¹q¹Ï¦p(B)¡C¦b2014¦~8¤ë6¤é²M±á¬ðµM©I§l§xÃø¡A¤D«æ©¹«æ¶E³¡¨D¶E¡A¾ÚºÙ¯f¤H¤w¦³¤ß±ª¡B¯Ý´e¤Î¶¡·²©Ê©I§l§xÃø¤@¶g¡C²z¾ÇÀˬd¡GT/P/R= 36.9/79/18¡FBP 119/73 mmHg¡F«æ¯fª¬¡AªÍ³¡²V¿B©I§l­µ¡A¤ßŦ¤j¤p©|¥i¡A¥¼¦³¤ßÂø­µ¤ÎS3©ÎS4¡A¾l¤§²zÀË©|µL²§±`¡C¨ä¤ß¹q¹Ï(C) ¤Î¯Ý³¡X¥ú©M¦å²GÀˬd¦p¹Ï¡C½Ð°Ý¦¹¯f¤H¤§¤ß«ß¤£¾ã¶EÂ_¬O¡G
A.Short-run ventricular tachycardia
B.Torsades de pointes
C.Atrial fibrillation
D.Wolff-Parkinson-White (WPW) syndrome with atrial fibrillation
E.Ventricular fibrillation
 
(D) 12. ²{¦~52·³¨k©Ê¯f¤H¡A¦]«æµo¯Ý¯k¨Ã¦³Âù¸}³Â¤ì«æ©¹«æ¶E³¡¨D¶E¡C®É¦³¦X¨Ö§N¦½¡A¦ýµLäú¤ß©Î¹Ã¦R¡A¤]¥¼¦³©ñ´²©Ê¯Ý¯k¡C¦åÀ£65/52mmHg; ¤ß¸õ52/¤À¡FÅé·Å36.7«×¡F©I§l18/¤À¡F¨ä¥L²z¾Ç©Ò¨£©|µL­«¤j²§±`¡C¯f¤H¬J©¹¯f¥v¦³¤Q¦h¦~°ª¦åÀ£¡A¤£³W«h¥ÎÃÄ¡A®a±Ú¦³«a¤ß¯f¡C¨äºò«æ¥Í¤ÆÀˬd¡GCK 78¡FCK-MB 26.3¡FTroponin I 0.012¡C½Ð°Ý¥»¯f¤HªºSTEMI³Ì¥i¯àªº«aª¬°Ê¯ßªý¶ë¦ì¸m¦b¡G
A.Proximal left anterior descending artery(LAD)
B.Proximal LAD beyond septal branch
C.Posterolateral right coronary artery(RCA)
D.Proximal RCA with Bezold-Jarish reaction
E.Proximal left circumflex artery
 
(E) 13. ¤@¦ì42·³ªº¨k©Ê¤W¯Z±Ú¨Ó¬ÝÅéÀ˳ø§i¡A¥L¨C©PºC¶]¤T¦¸¡A¨C¦¸¶]35¤ÀÄÁ¡A¶]¨B®É¤£´¿Ä±±o¯Ý´e©Î®ð³Ý¡C¦b¤u§@À£¤O¤jªº®É­Ô°¸º¸·|ı±o"¤ßŦ¤Ö¤F¤@¸õ"ªº·Pı¡A¦Ó³oºØ·Pı¤£·|«ùÄò¡A¤]¤£·|¦³ÀY·w¡C¥H«e¨S¦³¦í°|©Î¶}¤M¡A¦Û¤v·Pı°·±d¡A¨S¦³©âµÒ©Î³Ü°s¡C¨­ÅéÀˬd¦åÀ£ 126/72 mmHg¡A¤ß¸õ¨C¤ÀÄÁ68¦¸¡A©I§l¨C¤ÀÄÁ14¦¸¡A¨­Åé½è¶q«ü¼Æ(BMI)¬O23 kg/m2¡C¤ß­µÅ¥¶E¦b¥ª¤U¯Ý°©Ãä½t¦³¤£·|©ñ®gªº²Ä2/6«×¦¬ÁY¤ßÂø­µ¡AªÍ³¡©I§l­µ¥¿±`¡A¥|ªÏ¯ß·i¹ïºÙ¥¿±`¡A¤ß¹q¹ÏÀˬd¥¿±`¡C ¤U¤@¨B­n¦w±ÆªºÀˬd¬O¡H
A.24¤p®É¤ß¹q¹Ï
B.­¹¹D¤ßŦ¶W­µªi
C.¯Ý«e¤ßŦ¶W­µªi
D.¹B°Ê¤ß¹q¹Ï
E.¤£¥Î¶i¤@¨BÀˬd
 
(E) 14. 63·³¨k©Ê¦³²Ä¤G«¬¿}§¿¯f©M°ª¦åÀ£¡A¦P®É¦³°}µo©Ê¤ß©ÐÅÖºûŸ°Êªº¯f¥v¦Ó±µ¨ü¥]§t¦³metoprolol¡Ametformin©MwarfarinªºÃĪ«ªvÀø¡C¦]¬°ÁT«K¼ç¦å¿zÀ˶§©Ê¦w±Æ¤j¸zÃèÀˬd¡A¦]¬°¥i¯à·|¦³±ÄÀË (biopsy)ªº»Ý­n¡A­n¥ý°±¥Îwarfarin¡C¥L¤£´¿©âµÒ¡A¨S¦³¤¤­·©Î¥|ªÏ°ÊÀR¯ß¦åºÞªý¶ëªº¹L¥h¥v¡AÅéÀˮɦåÀ£¤ß¸õ¦b¥¿±`­È¡A¤ß«ß«h§e²{¤£³W«h(irregularly irregular)¡A©â¦åÀˬdINR¬O2.3¡C¦b¦¹®É»Ý­n°±¤îwarfarinªº±¡ªp¤U¡A·|±Ä¨úªº¸û«ê·í¨BÆJ¬O¡H
A.§ï¥Îaspirin
B.§ï¥Îclopidogrel
C.§ï¥Î§C¤À¤l¶q¨x¯À(low molecular weight heparin)
D.§ï¥Î¨x¯À(unfractionated heparin)
E.¤£¶·¨Ï¥Î¼È®Éªº´À¥NÃÄ«~
 
(A) 15. 70·³¨k©Ê¯f¤H¡A¦]¬°ÄY­«ªº¥¢¥NÀvÆ{¦å©Ê¤ß°IºÜ(decompensated congestive heart failure)¦í°|±µ¨üªvÀø¡A¦]¬°¬ðµo©Êªº¤ß«ÇÅÖºûŸ°Ê(Vf)¥¿¦b¶i¦æ«æ±Ï¡A¥Ø«e­è¶i¦æ§¹200µJ¦Õªº«D¦P¨BÅé¥~¥hŸ¹qÀ»¡Aºò±µµÛ¥hŸ¹qÀ»¤§«á¥ß¨è¶i¦æ¸û«ê·íªº°Ê§@¬O¡H
A.Ä~ÄòÅé¥~«ö¼¯CPR
B.µ¹¤©epinephrine
C.µ¹¤©amiodarone
D.½T»{¯ß·i
E.µ¹¤©vasopressin
 
(B) 16. 52·³¦³°ª¦åÀ£ªº¨k©Ê±wªÌ¡A±Æ§¿¥¿±`¡A¦]¬°¤j©ó¤@©PªºÂù¤UªÏ¤ô¸~©M©I§l·|³Ý¡Aª¦2¼h¼Ó±è§ó³Ý¦Ó¦í°|ªvÀø¡C¦í°|®É¥L±µ¨üÀR¯ßª`®g§Q§¿¾¯furosemide¤§«á¯gª¬¶i¨B¡A¤­¤Ñ«áÃĪ«½Õ¾ã¨ì¤fªAªº enalapril©Mfurosemide¡A¤ßŦ¶W­µªiÀˬd¥ª¤ß«Ç®g¥X²v35%¡A¨S¦³Ã¤½¤¯e¯f¡A¾ã­Ó¥ª¤ß«Ç¹B°Ê¤£¨}(global hypokinesia); ®Ö¤lÂå¾ÇÄé¬yÀˬd¨S¦³©úÅ㪺§½³¡¯Ê¦å¡C¥Ø«e¥Lªº¦åÀ£¬O136/88mmHg¡A¤ß¸õ¨C¤ÀÄÁ80¦¸¡A©I§l¨C¤ÀÄÁ15¦¸¡A¨­ÅéÀˬd¨S¦³ÀVÀR¯ß«ã±i¡A¨S¦³²Ä¤T¤ß­µ¡A¨S¦³ªÍ³¡Åo­µ(moist rales)¡AÂù¤UªÏ¤w¸g¨S¦³¤ô¸~¡C¥Òª¬¸¢¼Æ­È¥¿±`¡A¤ß¹q¹Ï¥¿±`Äu©Ê¸`«ß¡A¨S¦³¯f²z©ÊQªi¡C¦¹®É¥[¤W¤U¦C­þ¤@ºØÃĪ«¸û¦X¾A¡H
A.Amlodipine
B.Carvedilol
C.Hydralazine + isosorbide dinitrate
D.Doxazosin
E.Spironolactone
 
(C) 17. 76·³¤k©Ê°ª¦åÀ£¯f¤H¸g¾ú¯Ý¤f¯kµh¤T¤Ñ¤§«á¥Ñ®a¤H³­¦P´NÂå¡A·í¦o¨ìÂå°|«æ¶E®É¯Ýµh¤w¸g½w¸Ñ¡Aªì¨Bµo²{¦o¦³ST¸`¬q¤W¤É«¬«e¾À¤ß¦Ù±ð¶ë¡C¨ì°|¨â¤p®É¤§«á¦o¬ðµMµo¥Í©I§l¤£¶¶¡A¼@¯P³Ý®§©M¦åÀ£¤U­°¦Óºò«æ¶i¦æ®ðºÞ´¡ºÞ¡AX¥úÀˬdµo²{§óÂX¤jªº¤ßŦ»PªÍ¤ô¸~¡A¨Ã»Ý­n¥ÎDopamine¶}©lÀ°¦£ºû«ù¦åÀ£¡C¨­ÅéÀˬd¦åÀ£¬O90/60mmHg¡A¤ß¸õ¨C¤ÀÄÁ122¦¸¡A©I§l¨C¤ÀÄÁ16¦¸¡A¦b¦oªº¥ª¥k¯Ý°©Ãä½tÅ¥¨ì²Ä4/6¯Å¥þ¦¬ÁY´Á¤ßÂø­µ¡A¥i¥HIJ¶E¨ì¾_Ÿ(thrill)¡AÂù°¼ªÍ³¡¥X²{Åo­µ(rales)¡C¤U¦C­þ¤@­Ó¶EÂ_¤ñ¸û¥i¯à­n¥ý¦Ò¼{¡H
A.¥D°Ê¯ß­éÂ÷
B.¥ª¤ß«Ç½F
C.¤ß«Ç¤¤»J¯Ê·l
D.¥k¤ß«Ç±ð¶ë
E.¤ß¥]¶ñ¶ë(cardiac tamponade)
 
(C) 18. 68·³¤k©Ê±wªÌ¦]¬°¬ðµM¥X²{ªº¤ß±ª¦X¨ÖÀY·w¡A©I§l·|³Ýµ¥ª¬ªp¨Ó¨ì«æ¶E«Ç¡C¦o¦³°ª¦åÀ£ªº¯f¥v¡A«e¤@­Ó¤ë­è¶i¦æªºÀˬd¡A¤ßŦ¶W­µªiÅã¥Ü¥ª¤ß«Ç¦¬ÁY¥\¯à¥¿±`¡A¤ß¸õ¬OÄu©Ê¤ß«ß¡C¥Ø«e¥¿¨Ï¥ÎACE inhibitor¡A§Q§¿¾¯©Mªü´µ¤ÇÆFªvÀø¡C¥­¤é¦åÀ£±±¨î¦b¥¿±`¼Æ­È¡C·í¦o¨ì¹F«æ¶E®É¡A´ú±oªº¥Í©R¼x¶H¡G¦åÀ£80/60mmHg¡A¤ß¸õ150¦¸/¤ÀÄÁ¡A©I§l30¦¸/¤ÀÄÁ¡A¨Ï¥Î40%®ñ®ð­±¸nªºSpO2¬O80%¡C¤ßŦªº¨­ÅéÀˬdµo²{¤£³W«hªº§Ö³t¤ß¸õ¡AS1¤ß­µÅ¥¶E®ÉÁn­µ¥X²{¤j¤pÅܤơAÂù°¼¤U¤T¤À¤§¤@ªºªÍ³¡¦³ÀãÅo­µ¡A¤ß¹q¹Ï§e²{¤ß©ÐÅÖºûŸ°Ê¡C¦¹®Éªººò«æ³B²z¤U¦C¤ñ¸û¦X¾Aªº¤@¶µ¬O¡H
A.Adenosine
B.Amiodarone
C.Cardioversion
D.Diltiazem
E.Metoprolol
 
(E) 19. 60·³ªº¨k©Ê¦]¬°¥ª°¼¦Ø½¤¯kµh·Pı¦Ó´NÂå¡A¥Lªº¯kµh¥X²{¤j¬ù¤@¶g¤F¡A¨C¦¸µo¥Í®É·|µh¼Æ­Ó¤p®É¡A¦pªG½ö¤U·|§ó¯kµh¡C¥L´¿¸ÕµÛªA¥Î´¶®³¯k¡A¥u¯àµy·L´î»´¯kµh·P¡A¦ý¥Lµo²{¦pªG§¤µÛ±N¤W¥b¨­¶É¦V«e¤è¯à¼È®ÉÅý¯kµh·P®ø¥¢¡C¥L¦^¾Ð¦Û¤v¦b¤C­Ó¤ë¤§«e´¿³Q¶EÂ_¦³«æ©Ê¤ß¥]½¤ª¢¡A¨º®É¦Y¤FÂå®v¶}ªº¤îµhÃÄ7¤Ñ¤§«á´N¦n¤F¡C±wªÌ¦b³Ìªñ¤T¤Ñ¦³»´·Lµo¿N¡A¦ý¨S¦³«y¹Â©Î¬y»ó¤ô¡A¤]¨S¦³®È¦æ¡C¨­ÅéÀˬd®É¥Í©R¼x¶H¡G¦åÀ£128/68mmHg¡A©I§l16¦¸/¤ÀÄÁ¡A¤ß¸õ98¦¸/¤ÀÄÁ¡A¨S¦³ÀVÀR¯ß¹ªµÈ¡A¦ý¦³¥ª°¼¯Ý°©½tÅ¥¨ì¦³¤G­Ó²Õ¦¨¦¨¥÷ªº¤ß¥]¼¯À¿­µ¡AªÍ³¡Å¥¶E¨S¦³­ý»ï­µ¡A¤â¸}¨S¦³¤ô¸~¡A¤ß¹q¹Ï¬OÄu©Ê¤ ß«ß¡A¨S¦³ST¸`¬qÅܤơC¦¹®É·|¦Ò¼{ªºªvÀø¤è¦¡¡A¦óªÌ¤ñ¸û«ê·í¡H
A.Àˬd¯Ý³¡¹q¸£Â_¼h
B.¤ß¥]¤Á°£³N
C.Azathioprine
D.Prednisolone
E.Colchicine©Maspirin
 
(D) 20. 73·³¤k©Ê¦³²Ä¤G«¬¿}§¿¯f¡A°ª¦åÀ£¡A°ª¦å¯×¦n¦h¦~¤F¡A¦o«e¨Ó¦^¶E¬Ý³ÌªñªºÀˬd³ø§i¡C¥Ø«e¦o¥¿±µ¨üolmesartan, metformin©MpravastatinªºªvÀø¡C¦o¦³±µ¨üÂå®vªº«Øijºû«ù©T©w¹B°Ê¡A°ªÅÖ§C¯×¶¼­¹¡A¦P®É±`Äá¨ú¤ôªG»P½­µæ¡C¨S¦³ÃĪ«¹L±Ó¥v¡C¦^¶E®É¥Í©R¼x¶H¬O¡G¦åÀ£122/72mmHg¡A¤ß¸õ72¦¸/¤ÀÄÁ¡A©I§l15¦¸/¤ÀÄÁ¡A¤ß¡B¯Ý¡B¸¡³¡»P¥|ªÏªº¨­ÅéÀˬd«h¨S¦³¯S®íµo²{¡C¹êÅç«ÇÀˬd¼Æ­È¦p¤U¡GHbA1c : 6.5%¡AÁ`Áx©T¾J116mg/dL¡A§C±K«×Áx©T¾J(LDL-C)51mg/dL¡A°ª±K«×Áx©T¾J(HDL-C)57mg/dL¡A¤T»Ä¥Ìªo¯×(TG)40mg/dL¡C¯f¤H§Æ±æ±µ¨ü§¹µ½ªº·ÓÅU¡A½Ð°Ý·|µ¹¤©ªº¥ÎÃÄ«Øij¡A¤U¦C¦óªÌ¬°¨Î¡H
A.¨Ï¥Îclopidogrel
B.¼W¥[­°¦å¯×ªºÃĪ«
C.¨Ï¥Îaspirin©Mdipyridamole
D.¨Ï¥Îaspirin
E.¨Ï¥Îaspirin©Mclopidogrel
 
(A) 21. 50·³ªº¤k©Ê´¿¦b13¦~«e¦]¨ÅÀù±µ¨ü¤â³N¤Á°£¥k°¼¨Å©Ð¥H¤Î³N«áªº©ñ®g½uªvÀø¡C¦b¥~¬ì³N«áªº³W«h°lÂ̡ܸA¦oªºª¬ªpí©w¡A¨S¦³ÅܤơCª½¨ì¦o³Ìªñ¤T­Ó¤ë¸Ì¡A¦o·P¨ì¹B°Ê®É·|²¤¬°¯Ý´e¡A³Ìªñ¤G­Ó¤ë¤º«hºCºC¥X²{ª¦¤T¼h¼Ó±è®É¦³¤@ÂI³Ý¡C¨­ÅéÀˬd®É¦oªºÅé·Å¥¿±`¡A¦åÀ£¡G150/43mmHg¡A¤ß¸õ80¦¸/¤ÀÄÁ¡A©I§l14¦¸/¤ÀÄÁ¡CÀVÀR¯ß¨S¦³¹ªµÈ¡A¦ý·|Æ[¹î¨ì¥[±j¦Ó§Ö³tªºÀV°Ê¯ßªi¤W¤É»P¤U­°¡A¤ß­µµo²{´î¤pªºS2¤ß­µ¡A¦ý¨S¦³S3¡A¥ª°¼²Ä¤T¦Ø¶¡¯Ý°©½t«h¥X²{°ªÀW²v¡A²Ä2/6¯ÅªºµÎ±i´Áº¥´î©Ê¤ßÂø­µ¡A³Ì¤j¤ß¦y·i°ÊÂI«h¦V¥~¦V¤U°¾²¾¡A¨S¦³¥X²{¨x¡ÐÀVÀR¯ß¤Ï®gªi(Hepatojugular reflux)¡C¤U¦C­þ¤@­Ó±¡ªp¸û¯à¸ÑÄÀ«e­zµo²{¡H
A.¥D°Ê¯ßä°j¬y(Aortic valve regurgitation)
B.¤ß¥]¶ñ¶ë(Cardiac tamponade)
C.­­¨î©Ê¤ß¦Ù¯fÅÜ(Constrictive pericarditis)
D.«]­­©Ê¤ß¥]½¤ª¢(Restrictive cardiomyopathy)
E.ÄY­«¤T¦yä°j¬y(Severe tricuspid valve regurgitation)
 
(E) 22. 22·³ªº¨k©Ê¡A¥X¥Í®É¬O­Ó¦­²£¨à¡A¥L°O±o¤÷¥À»¡¥L±q¤p´N³QÂå®v¶EÂ_¦³¤ßÂø­µ¦ý¨S¦³¶}¹L¤M¡A¦ý¨D¾Ç¤¤»P¦P¯Z¾Ç¥Í¦bÅé¯à¹B°Ê¤Wªºªí²{¬Ûªñ¡A¨S¦³¯S§Oªº¦a¤è¡A¤£´¿¦]¯Ý³¡ªº¯gª¬©Î¤£µÎªA¬Ý¹L¯f¡C¨­ÅéÀˬd®É¦åÀ£¡G116/82mmHg¡A³Ì¤j¤ß¦y·i°ÊÂI¨S¦³©úÅã¦ì²¾¡A¦b¥ª°¼¯Ý°©½t²Ä¤G¦Ø¶¡³B¦³¤@­Ó²Ä3/6¯Åªº³sÄòªº¡A¹³¾÷±ñªº( continuous-machinery )ªºÁn­µ¥X²{¡A³o­ÓÁn­µ¸ó¶V¤F¦¬ÁY©MµÎ±i´Á¡A³o­ÓÁn­µ¦b¥ª°¼Âê°©¤U¤è¤]¥i¥HÅ¥¨£¡C¥Lªº¤â¸}¯ß·i±j®z¬O¥¿±`¹ïºÙ¡A¤]¨S¦³¥X²{¯ß·i©µ¿ð¡A¨S¦³ªSª¬«ü©ÎµoÖæ¡C¯Ý³¡X¥ú©M¤ß¹q¹ÏÀˬd«h¥¿±`¡C¤U¦C­þ¤@­Óª¬ªp¸û²Å¦X³o­Óµo²{¡H
A.Ventricular septal defect
B.Aortic coarctation
C.Atrial septal defect
D.Aortic valve stenosis
E.Patent ductus arteriosus
 


< ¤@¡³¤T¦~«×¸ÕÃD¥Ø¿ý >